October 29, 2025 — CAMBRIDGE, Mass. — Wave Life Sciences Ltd. (Nasdaq: WVE) announced positive data from its INLIGHT clinical trial of WVE-007, a GalNAc-siRNA, for obesity treatment, during its annual analyst and investor Research Day.
The INLIGHT trial showed dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007, exceeding levels that led to weight loss in preclinical models. The company reports that WVE-007 is generally safe and well tolerated to date. The trial also demonstrated that Activin E reduction in the lowest dose cohort was sustained through six months, supporting once or twice a year dosing.
Wave Life Sciences anticipates multiple clinical data updates from INLIGHT, including body composition and body weight, starting in 4Q 2025. In addition, they announced WVE-008, a PNPLA3 RNA editing candidate for liver disease, with CTA submission anticipated in 2026. Preclinical data supports Wave’s emerging pipeline of hepatic and extra-hepatic RNA editing and siRNA programs, with an emerging modality that adds capability to simultaneously edit and silence two unique targets with a single oligonucleotide construct.
According to Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences, the company is excited to be observing potent, durable, and dose-dependent Activin E reductions with single doses of WVE-007. Bolno added that Wave continues to lead the field in RNA editing and is in a unique position to unlock tremendous value from its robust RNA medicines pipeline with multiple planned clinical updates across its RNA editing and RNAi programs.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
Source: Wave Life Sciences Ltd.
